OceansBio Co., Ltd.
KKRX:3321902,275.00
KRW
-400.00
(-14.95%)
ISIN
KR7332190008
Return %
Stock
S&P 500
1Y
-54.50
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Changwon South Korea
- IPO Date
- Jan 14, 2025
- Website
- oceansbio.com
- Similar Companies
- Business
- OceansBio Co., Ltd. is a South Korea-based bioelectronic technology and medical device company primarily engaged in the research, development, and commercialization of electroceuticals, neuromodulation platforms, and digital healthcare solutions. The company focuses on non-invasive and micro-implantable electronic therapies designed to treat neurological, psychiatric, and autonomic nervous system disorders through targeted electrical stimulation. The company's product and service portfolio includes non-invasive transcutaneous vagus nerve stimulation (tVNS) wearable medical devices for the therapeutic management of depression, anxiety, insomnia, and chronic stress; micro-implantable pulse generators and bioelectronic stimulators developed for chronic neurological indications such as drug-resistant epilepsy and neuroinflammatory conditions; proprietary biocompatible neural interface electrodes and biosignal acquisition sensors; companion digital therapeutic software applications and mobile health platforms for treatment personalization, patient compliance tracking, and real-time stimulation telemetry; and clinical analytics systems for healthcare providers and clinical research organizations. OceansBio operates through its Bioelectronic Medicine and Digital Health segments, targeting hospitals, psychiatric and neurology clinics, academic medical centers, and direct-to-patient home healthcare markets. In recent developments, OceansBio Co., Ltd. has accelerated the clinical evaluation and regulatory approval pipelines for its flagship transcutaneous vagus nerve stimulation systems, initiating multicenter clinical trials in partnership with domestic university hospitals and research institutions. The company has actively pursued international regulatory compliance, establishing strategic roadmaps for medical device clearance with both the South Korean Ministry of Food and Drug Safety (MFDS) and overseas regulatory bodies including the United States Food and Drug Administration (FDA). In addition, OceansBio has broadened its strategic research alliances to develop next-generation closed-loop bioelectronic devices that integrate artificial intelligence-based biosignal feedback with automated stimulation adjustment, while strengthening its corporate capitalization to support manufacturing scaling and global commercialization initiatives. Founded in 2018, OceansBio Co., Ltd. is headquartered in South Korea and is publicly traded on the Korea Exchange (KRX: 332190).